| |  Online-Ressource |
|---|
| Verfasst von: | Harenberg, Job [VerfasserIn]  |
|---|
| | Hetjens, Svetlana [VerfasserIn] |
|---|
| | Erdle, Sandra [VerfasserIn] |
|---|
| | Krämer, Roland [VerfasserIn] |
|---|
| Titel: | Determination of the anticoagulant effects of new oral anticoagulants |
|---|
| Titelzusatz: | an unmet need |
|---|
| Verf.angabe: | Job Harenberg, Svetlana Marx, Sandra Erdle & Roland Krämer |
|---|
| E-Jahr: | 2014 |
|---|
| Jahr: | 10 Jan 2014 |
|---|
| Jahr des Originals: | 2012 |
|---|
| Umfang: | 7 S. |
|---|
| Fussnoten: | Gesehen am 09.08.2018 |
|---|
| Titel Quelle: | Enthalten in: Expert review of hematology |
|---|
| Ort Quelle: | Abingdon, Oxon : Taylor & Francis, 2008 |
|---|
| Jahr Quelle: | 2012 |
|---|
| Band/Heft Quelle: | 5(2012), 1, Seite 107-113 |
|---|
| ISSN Quelle: | 1747-4094 |
|---|
| Abstract: | Thromboembolic diseases require anticoagulation for their prevention and treatment. New oral anticoagulants, specifically direct factor Xa and thrombin inhibitors, were developed to overcome the limitations of conventional anticoagulants. Their benefit has been demonstrated using fixed doses without laboratory-guided dose adjustment for patients following elective knee and hip replacement, treatment of venous thromboembolism and prevention of embolic events in atrial fibrillation. These anticoagulants are excreted by glomerular filtration at a rate of between 25 and 80%. Thus, lower doses are required for patients with impaired renal function. Therefore, determination of the anticoagulant effects may be needed in other specific patient populations. Prothrombin time, activated partial thromboplastin time, prothrombin-induced clotting time, ecarin clotting time, hemoclot assay, other specific coagulation assays and chromogenic substrate are available to determine the effect of the anticoagulants. Standardization of methods, development of point-of-care tests and identification of patient groups is ongoing. |
|---|
| DOI: | doi:10.1586/ehm.11.79 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: http://dx.doi.org/10.1586/ehm.11.79 |
|---|
| | Volltext: https://doi.org/10.1586/ehm.11.79 |
|---|
| | DOI: https://doi.org/10.1586/ehm.11.79 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | activated partial thromboplastin time |
|---|
| | apixaban |
|---|
| | atrial fibrillation |
|---|
| | chromogenic substrate assays |
|---|
| | dabigatran |
|---|
| | oral anticoagulants |
|---|
| | prothrombin time |
|---|
| | prothrombinase-induced clotting time |
|---|
| | rivaroxaban |
|---|
| | venous thromboembolism |
|---|
| K10plus-PPN: | 1578427541 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Determination of the anticoagulant effects of new oral anticoagulants / Harenberg, Job [VerfasserIn]; 10 Jan 2014 (Online-Ressource)
